253 related articles for article (PubMed ID: 22472884)
21. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
[TBL] [Abstract][Full Text] [Related]
23. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
24. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
[TBL] [Abstract][Full Text] [Related]
25. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
26. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW
Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035
[TBL] [Abstract][Full Text] [Related]
27. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
28. Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
Field GC; Pavlyk I; Szlosarek PW
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903394
[TBL] [Abstract][Full Text] [Related]
29. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
Wangpaichitr M; Wu C; Bigford G; Theodoropoulos G; You M; Li YY; Verona-Santos J; Feun LG; Nguyen DM; Savaraj N
Anticancer Res; 2014 Dec; 34(12):6991-9. PubMed ID: 25503125
[TBL] [Abstract][Full Text] [Related]
30. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
31. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.
Yang TS; Lu SN; Chao Y; Sheen IS; Lin CC; Wang TE; Chen SC; Wang JH; Liao LY; Thomson JA; Wang-Peng J; Chen PJ; Chen LT
Br J Cancer; 2010 Sep; 103(7):954-60. PubMed ID: 20808309
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
33. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
[TBL] [Abstract][Full Text] [Related]
34. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
35. Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells.
Chung SF; Tam SY; Kim CF; Chong HC; Lee LM; Leung YC
Invest New Drugs; 2022 Oct; 40(5):895-904. PubMed ID: 35857203
[TBL] [Abstract][Full Text] [Related]
36. Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
Chung SF; Kim CF; Kwok SY; Tam SY; Chen YW; Chong HC; Leung SL; So PK; Wong KY; Leung YC; Lo WH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545874
[TBL] [Abstract][Full Text] [Related]
37. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
38. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation.
Singh PK; Deorukhkar AA; Venkatesulu BP; Li X; Tailor R; Bomalaski JS; Krishnan S
Mol Cancer Ther; 2019 Dec; 18(12):2381-2393. PubMed ID: 31395686
[TBL] [Abstract][Full Text] [Related]
39. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.
Roeksomtawin S; Navasumrit P; Waraprasit S; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Savaraj N; Ruchirawat M
Oncol Lett; 2018 Aug; 16(2):1529-1538. PubMed ID: 30008833
[TBL] [Abstract][Full Text] [Related]
40. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines.
You M; Savaraj N; Wangpaichitr M; Wu C; Kuo MT; Varona-Santos J; Nguyen DM; Feun L
Biochem Biophys Res Commun; 2010 Apr; 394(3):760-6. PubMed ID: 20227389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]